KEYFORM-008
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
- NCT05508867 ↗
- Completed
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on KEYFORM-008 (favezelimab/pembrolizumab in PD-(L)1-refractory relapsed or refractory classical Hodgkin lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYFORM-008 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 3 | |
| X threads | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Hodgkin Lymphoma
- Interventions
- favezelimab/pembrolizumab; bendamustine; gemcitabine
- Arms
- Favezelimab/Pembrolizumab · Experimental
- Chemotherapy (Bendamustine or Gemcitabine) · Active comparator
- Enrollment
- 203
- Primary outcomes
- Progression Free Survival (PFS) Per Lugano Response Criteria as Assessed by Investigator
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Oct 18, 2022
- Primary completion
- Sep 3, 2025
- Results posted
- Yes
- Registry record
- NCT05508867 · updated Sep 1, 2026